BRIEF published on 04/28/2026 at 20:40, 2 months 1 day ago GenSight Biologics announces its 2026 Combined General Meeting Shareholders Gene Therapy General Assembly Preparatory Documents GenSight Biologics
BRIEF published on 04/28/2026 at 20:40, 2 months 1 day ago GenSight Biologics Schedules Annual General Meeting for May 2026 Annual General Meeting Regulatory Compliance Shareholder Information Investor Relations Gene Therapy
PRESS RELEASE published on 04/28/2026 at 20:35, 2 months 1 day ago Inside Information / Other news releases GenSight Biologics to hold Annual General Meeting on May 19, 2026, in Paris. Shareholders can access preparatory documents online. Meeting details and documents available on company website Annual General Meeting Shareholders Preparatory Documents Meeting Details GenSight Biologics
BRIEF published on 04/07/2026 at 19:04, 2 months 22 days ago GenSight Biologics Reports Cash Status and Early Access Revenues Revenue Cash Position Gene Therapy GenSight Biologics Early Access Program
BRIEF published on 04/07/2026 at 19:04, 2 months 22 days ago GenSight Biologics: Financial Update and Progress on AAC Fundraising Treasury Gene Therapy GenSight Biologics Compassionate Access
PRESS RELEASE published on 04/07/2026 at 18:59, 2 months 22 days ago Inside Information / News release on accounts, results GenSight Biologics reports cash position and revenue from early access program as of March 31, 2026. Operating cash burn, fundraising, and treatment proceeds highlighted Revenue Fundraising Cash Position GenSight Biologics Early Access Program
BRIEF published on 03/27/2026 at 07:35, 3 months 3 days ago GenSight Biologics Reports 2025 Financial Performance Financing Activities Cash Runway R&D Expenses Regulatory Milestones Financial Results 2025
PRESS RELEASE published on 03/27/2026 at 07:30, 3 months 3 days ago Inside Information / News release on accounts, results GenSight Biologics reported estimated full-year consolidated financial results for 2025, highlighting key regulatory milestones achieved and cash runway projection through December 2026 Financial Results Phase III Trial GenSight Biologics Cash Runway Regulatory Milestones
BRIEF published on 03/23/2026 at 09:53, 3 months 6 days ago Heights Capital Management exceeds 8% of GENSIGHT BIOLOGICS' capital Capital Increase Threshold Crossing GenSight Biologics Capital And Voting Rights Heights Capital
BRIEF published on 03/18/2026 at 10:20, 3 months 11 days ago GenSight Biologics finalizes its €1.7 million fundraising round Ordinary Shares Fundraising GenSight Biologics Gene Therapies Risk Factors
Published on 06/30/2026 at 05:30, 2 hours 21 minutes ago Nano One Renews At-The-Market Equity Program
Published on 06/30/2026 at 02:00, 5 hours 51 minutes ago MedMira Reports Third Quarter Results FY2026
Published on 06/30/2026 at 00:05, 7 hours 46 minutes ago American Critical Minerals Announces Completion of Warrant Exercise Incentive Program
Published on 06/29/2026 at 23:46, 8 hours 5 minutes ago 1933 Industries Reports Third Quarter 2026 Financial Results
Published on 06/29/2026 at 22:01, 9 hours 50 minutes ago AIP Realty Trust Announces Voting Results of Annual General and Special Meeting of Unitholders
Published on 06/30/2026 at 07:30, 21 minutes ago REINET INVESTMENTS S.C.A. SHARE BUYBACK PROGRAMME – UPDATE 30 JUNE 2026
Published on 06/30/2026 at 07:30, 21 minutes ago Mutares portfolio company Amaneos completes acquisition of European Automotive Lighting Business from Magna as strategic add-on for LMS
Published on 06/30/2026 at 07:30, 21 minutes ago Just – Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for Biologics
Published on 06/30/2026 at 07:13, 38 minutes ago African Guarantee Fund appoints Mr. Constant N’ZI as Group Chief Executive Officer
Published on 06/30/2026 at 07:05, 46 minutes ago Infracore SA communicates the decision of the Swiss Takeover Board
Published on 06/30/2026 at 07:30, 21 minutes ago Gimv sells its stake in AlpenBlu Clinics (formerly Les Psy Réunis), a Swiss provider of outpatient mental healthcare, to Impact Healthcare.
Published on 06/30/2026 at 07:00, 51 minutes ago bioMérieux submits 510(k) to U.S. FDA for the latest versions of the BIOFIRE® FILMARRAY® Gastrointestinal Panels to enhance detection of gastrointestinal pathogens
Published on 06/29/2026 at 18:30, 13 hours 21 minutes ago Accor and H World Group expand long-term partnership across direct booking and loyalty platforms
